AN2 Therapeutics, Inc.
ANTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 4.17 | -0.04 | -0.15 |
| FCF Yield | -119.66% | -11.02% | -22.89% | -7.10% |
| EV / EBITDA | -0.39 | 95.43 | -2.91 | -12.82 |
| Quality | ||||
| ROIC | -66.65% | -55.84% | -44.26% | -34.73% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.96 | 0.82 | 0.82 | 0.95 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 7.56% | -59.25% | -63.36% | -281.88% |
| Safety | ||||
| Net Debt / EBITDA | 0.42 | -3.19 | 0.66 | 0.56 |
| Interest Coverage | 0.00 | 0.00 | -82.22 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -10,058.83 | 0.00 |